@ucsfcancer.bsky.social’s
Dr Laura van’t Veer is this year’s McGuire Award recipient for her work in molecular diagnostics, including Mammaprint. Congratulations! 🎉 👏🏻
#SABCS24
Dr Laura van’t Veer is this year’s McGuire Award recipient for her work in molecular diagnostics, including Mammaprint. Congratulations! 🎉 👏🏻
#SABCS24
December 11, 2024 at 5:43 PM
@ucsfcancer.bsky.social’s
Dr Laura van’t Veer is this year’s McGuire Award recipient for her work in molecular diagnostics, including Mammaprint. Congratulations! 🎉 👏🏻
#SABCS24
Dr Laura van’t Veer is this year’s McGuire Award recipient for her work in molecular diagnostics, including Mammaprint. Congratulations! 🎉 👏🏻
#SABCS24
Met with the medical oncologist today finally…we’ve been waiting for the mammaprint results which took forever. Found out they are NOT recommending chemo upfront, and going straight to hormone therapy, surgery, and radiation. Chemo scared me the most of all, so this is amazing.
October 16, 2025 at 1:08 AM
Met with the medical oncologist today finally…we’ve been waiting for the mammaprint results which took forever. Found out they are NOT recommending chemo upfront, and going straight to hormone therapy, surgery, and radiation. Chemo scared me the most of all, so this is amazing.
Post-hoc TAILORx analysis: In HR+/HER2-, LN- breast cancer w/ RS ≥31, anthracycline (T-AC) improved 5-year DRFI (96% vs 91%, aHR 0.32, p=0.009) and DRFS vs TC. Benefit strongest in tumors >2cm, increasing with RS
Results are alligned w/ other MammaPrint High 2 results
@oncoalert.bsky.social
Results are alligned w/ other MammaPrint High 2 results
@oncoalert.bsky.social
December 13, 2024 at 3:57 PM
Post-hoc TAILORx analysis: In HR+/HER2-, LN- breast cancer w/ RS ≥31, anthracycline (T-AC) improved 5-year DRFI (96% vs 91%, aHR 0.32, p=0.009) and DRFS vs TC. Benefit strongest in tumors >2cm, increasing with RS
Results are alligned w/ other MammaPrint High 2 results
@oncoalert.bsky.social
Results are alligned w/ other MammaPrint High 2 results
@oncoalert.bsky.social
Her policies led to reimbursement of 33 new orphan drugs over five years, many in oncology, and coverage for advanced diagnostics such as next‑generation sequencing and gene expression profiling tests (e.g., Mammaprint, Oncotype DX) to better target or avoid chemotherapy.
February 18, 2026 at 11:48 AM
Her policies led to reimbursement of 33 new orphan drugs over five years, many in oncology, and coverage for advanced diagnostics such as next‑generation sequencing and gene expression profiling tests (e.g., Mammaprint, Oncotype DX) to better target or avoid chemotherapy.
Presenting 3 works using #Nextflow to analyse exome (Sarek's Pipeline) by Cell Death Receptors, Mammaprint panel Genes and Oncotype DX panel Genes. Simpósio realised on Ribeirão Preto - Brasil about Susceptibilidade Genética Aplicada à Saúde.
#NGS #exome #Nextflow #GenomasSUS #GenomasBrasil
#NGS #exome #Nextflow #GenomasSUS #GenomasBrasil
November 20, 2024 at 1:05 PM
Presenting 3 works using #Nextflow to analyse exome (Sarek's Pipeline) by Cell Death Receptors, Mammaprint panel Genes and Oncotype DX panel Genes. Simpósio realised on Ribeirão Preto - Brasil about Susceptibilidade Genética Aplicada à Saúde.
#NGS #exome #Nextflow #GenomasSUS #GenomasBrasil
#NGS #exome #Nextflow #GenomasSUS #GenomasBrasil
Laura van ’t Veer en René Bernards, toen beiden verbonden aan het Nederlands Kanker Instituut, samen aan de wieg van de MammaPrint: een borstkankertest gebaseerd op genonderzoek:
www.newscientist.nl/blogs/de-uit...
www.newscientist.nl/blogs/de-uit...
De uitvinding: borstkankertest MammaPrint
Elke week bespreekt New Scientist-hoofdredacteur Jim Jansen een bijzondere uitvinding. Deze keer: de borstkankertest MammaPrint.
www.newscientist.nl
March 30, 2026 at 8:58 AM
Laura van ’t Veer en René Bernards, toen beiden verbonden aan het Nederlands Kanker Instituut, samen aan de wieg van de MammaPrint: een borstkankertest gebaseerd op genonderzoek:
www.newscientist.nl/blogs/de-uit...
www.newscientist.nl/blogs/de-uit...
Biological characteristics of high risk hormone receptor positive breast cancer - an analysis based on ISPY-2 data and Yale Breast team. #bcsm
pubmed.ncbi.nlm.nih.gov/39561272/
pubmed.ncbi.nlm.nih.gov/39561272/
Hormone Receptor Positive HER2-negative/MammaPrint High-2 Breast Cancers Closely Resemble Triple Negative Breast Cancers - PubMed
In conclusion, HR+/MP-H2 cancers closely resemble TN breast cancers in transcriptional and clinical features and benefit from similar treatment strategies.
pubmed.ncbi.nlm.nih.gov
November 29, 2024 at 11:33 AM
Biological characteristics of high risk hormone receptor positive breast cancer - an analysis based on ISPY-2 data and Yale Breast team. #bcsm
pubmed.ncbi.nlm.nih.gov/39561272/
pubmed.ncbi.nlm.nih.gov/39561272/
#breastcancer - Своевременното персонализиране на лечението на рака на гърдата води до добри резултати- www.linkedin.com/posts/lifesc... -следете @nmgenomix.bsky.social за повече новини
Survival outcomes for patients with invasive lobular cancer by MammaPrint: Results from the MINDACT phase III trial | Dimitar Georgiev
За съвременната наука ракът на гърдата отдавна не е едно заболяване, а букет от различни хистологично видове карциноми /разликите се определят със сложни и комплексни патоанатомични изследвания/, коит...
www.linkedin.com
October 17, 2025 at 4:33 AM
#breastcancer - Своевременното персонализиране на лечението на рака на гърдата води до добри резултати- www.linkedin.com/posts/lifesc... -следете @nmgenomix.bsky.social за повече новини
6/
Gene expression was a breakthrough 20 years ago.
Despite academic ubiquity, only OncotypeDx, MammaPrint, and ProSigna actually improve breast cancer decisions.
Wrong data choice kills your model before training starts.
Gene expression was a breakthrough 20 years ago.
Despite academic ubiquity, only OncotypeDx, MammaPrint, and ProSigna actually improve breast cancer decisions.
Wrong data choice kills your model before training starts.
January 21, 2026 at 2:15 PM
6/
Gene expression was a breakthrough 20 years ago.
Despite academic ubiquity, only OncotypeDx, MammaPrint, and ProSigna actually improve breast cancer decisions.
Wrong data choice kills your model before training starts.
Gene expression was a breakthrough 20 years ago.
Despite academic ubiquity, only OncotypeDx, MammaPrint, and ProSigna actually improve breast cancer decisions.
Wrong data choice kills your model before training starts.
Gene-expression methods have become clinically relevant elsewhere, but only after validation for specific uses.
Examples include Oncotype DX and MammaPrint in breast cancer, and PrismRA in rheumatoid arthritis.
Examples include Oncotype DX and MammaPrint in breast cancer, and PrismRA in rheumatoid arthritis.
July 3, 2026 at 3:33 PM
Gene-expression methods have become clinically relevant elsewhere, but only after validation for specific uses.
Examples include Oncotype DX and MammaPrint in breast cancer, and PrismRA in rheumatoid arthritis.
Examples include Oncotype DX and MammaPrint in breast cancer, and PrismRA in rheumatoid arthritis.
A 10-gene signature can now predict recurrence risk for HR+/HER2- early breast cancer #EBC patients post-chemo-endocrine therapy.
@myesmo.bsky.social @breastcancerorg.bsky.social
#Onco404 #Cancer #Kanser #BreastCancer #MemeKanseri #OncotypeDX #MammaPrint #EndoPredict #Prosigna #PAM50 #GGI #MedSky
@myesmo.bsky.social @breastcancerorg.bsky.social
#Onco404 #Cancer #Kanser #BreastCancer #MemeKanseri #OncotypeDX #MammaPrint #EndoPredict #Prosigna #PAM50 #GGI #MedSky
May 14, 2025 at 7:21 PM
A 10-gene signature can now predict recurrence risk for HR+/HER2- early breast cancer #EBC patients post-chemo-endocrine therapy.
@myesmo.bsky.social @breastcancerorg.bsky.social
#Onco404 #Cancer #Kanser #BreastCancer #MemeKanseri #OncotypeDX #MammaPrint #EndoPredict #Prosigna #PAM50 #GGI #MedSky
@myesmo.bsky.social @breastcancerorg.bsky.social
#Onco404 #Cancer #Kanser #BreastCancer #MemeKanseri #OncotypeDX #MammaPrint #EndoPredict #Prosigna #PAM50 #GGI #MedSky
Maar ze waren wel heel eerlijk met mij over toch grote twijfel chemo. Ondanks negatieve mammaprint.
Uiteindelijk samen met oncologe (en haar voorkeur) gekozen voor medicatie (hormoonremmers, zwevende kankercellen bestrijden en infusen tegen botontkalking). Gaat traject van 3 jaar worden.
Uiteindelijk samen met oncologe (en haar voorkeur) gekozen voor medicatie (hormoonremmers, zwevende kankercellen bestrijden en infusen tegen botontkalking). Gaat traject van 3 jaar worden.
July 8, 2025 at 3:24 PM
Maar ze waren wel heel eerlijk met mij over toch grote twijfel chemo. Ondanks negatieve mammaprint.
Uiteindelijk samen met oncologe (en haar voorkeur) gekozen voor medicatie (hormoonremmers, zwevende kankercellen bestrijden en infusen tegen botontkalking). Gaat traject van 3 jaar worden.
Uiteindelijk samen met oncologe (en haar voorkeur) gekozen voor medicatie (hormoonremmers, zwevende kankercellen bestrijden en infusen tegen botontkalking). Gaat traject van 3 jaar worden.
🔍 Why It Matters
☑️ 20% of HR+/HER2- EBC patients relapse despite adjuvant C-ET.
✅ Existing tools (e.g., 21-gene, 70-gene) guide chemo decisions but fail to pinpoint high-risk patients after C-ET.
#Onco404 #Cancer #Kanser #BreastCancer #MemeKanseri #OncotypeDX #MammaPrint #Prosigna #OncSky #MedSky
☑️ 20% of HR+/HER2- EBC patients relapse despite adjuvant C-ET.
✅ Existing tools (e.g., 21-gene, 70-gene) guide chemo decisions but fail to pinpoint high-risk patients after C-ET.
#Onco404 #Cancer #Kanser #BreastCancer #MemeKanseri #OncotypeDX #MammaPrint #Prosigna #OncSky #MedSky
May 14, 2025 at 7:21 PM
🔍 Why It Matters
☑️ 20% of HR+/HER2- EBC patients relapse despite adjuvant C-ET.
✅ Existing tools (e.g., 21-gene, 70-gene) guide chemo decisions but fail to pinpoint high-risk patients after C-ET.
#Onco404 #Cancer #Kanser #BreastCancer #MemeKanseri #OncotypeDX #MammaPrint #Prosigna #OncSky #MedSky
☑️ 20% of HR+/HER2- EBC patients relapse despite adjuvant C-ET.
✅ Existing tools (e.g., 21-gene, 70-gene) guide chemo decisions but fail to pinpoint high-risk patients after C-ET.
#Onco404 #Cancer #Kanser #BreastCancer #MemeKanseri #OncotypeDX #MammaPrint #Prosigna #OncSky #MedSky
В интервю за Pharmacy Times лекари обсъждат как все по-често решението може да се подпомогне от геномен тест, който показва колко агресивен е #туморът на молекулярно ниво и какъв е #рискът той да се върне. Вижте тук nmgenomix.com/mammaprint-t...
#антрациклини #туморът #рискът #персонализирана #медицина #геномен #анализ #лекар #пациент | NM Genomix
В ранния рак на гърдата един от най-трудните въпроси е: „На тази жена наистина ли ѝ трябва по-тежка химиотерапия?“. Особено когато говорим за #антрациклини, ефективни лекарства, но с по-сериозни риско...
www.linkedin.com
February 20, 2026 at 9:06 AM
В интервю за Pharmacy Times лекари обсъждат как все по-често решението може да се подпомогне от геномен тест, който показва колко агресивен е #туморът на молекулярно ниво и какъв е #рискът той да се върне. Вижте тук nmgenomix.com/mammaprint-t...
70-gene signature MammaPrint for early-stage HR-positive, HER2-negative #BreastCancer: outcome in the MINDACT trial for key clinical-pathological high-risk subgroups. www.ejcancer.com/article/S095...
70-gene signature MammaPrint for early-stage HR-positive, HER2-negative breast cancer: outcome in the MINDACT trial for key clinical-pathological high-risk subgroups
Adjuvant chemotherapy (ACT) can be safely omitted in patients above 50 years of age
with stage I-II hormone receptor positive (HR+) HER2-negative (HER2-) breast cancer
and a low-risk 70-gene signature...
www.ejcancer.com
September 18, 2026 at 8:49 AM
70-gene signature MammaPrint for early-stage HR-positive, HER2-negative #BreastCancer: outcome in the MINDACT trial for key clinical-pathological high-risk subgroups. www.ejcancer.com/article/S095...
'Chemo had bij mij meer kapot gemaakt dan genezen'
'Chemo had bij mij meer kapot gemaakt dan genezen'
In 2012 werd er borstkanker geconstateerd bij Lilianne Hopstaken. Ze vroeg om een MammaPrint en kon daardoor de chemotherapie overslaan.
nos.nl
August 22, 2026 at 1:17 AM
'Chemo had bij mij meer kapot gemaakt dan genezen'
NM Genomix подарява OncoSeek тест за близък на пациента
При заявяване на Signatera, MammaPrint, OncoDEEP или OncoSELECT всеки пациент получава един OncoSeek тест за свой роднина като подарък. Научете повече 👇
nmgenomix.com/nm-genomix-%...
При заявяване на Signatera, MammaPrint, OncoDEEP или OncoSELECT всеки пациент получава един OncoSeek тест за свой роднина като подарък. Научете повече 👇
nmgenomix.com/nm-genomix-%...
NM Genomix подарява OncoSeek на близък на пациента при заявяване на избрани онкологични изследвания
В NM Genomix вярваме, че грижата за здравето не приключва с пациента. Именно затова стартираме нова инициатива, насочена към хората, които стоят до него във всеки етап от лечението.
https://nmgenomix.com/nm-genomix-подарява-oncoseek-на-близък-на-пациента-при/
August 6, 2026 at 6:53 AM
NM Genomix подарява OncoSeek тест за близък на пациента
При заявяване на Signatera, MammaPrint, OncoDEEP или OncoSELECT всеки пациент получава един OncoSeek тест за свой роднина като подарък. Научете повече 👇
nmgenomix.com/nm-genomix-%...
При заявяване на Signatera, MammaPrint, OncoDEEP или OncoSELECT всеки пациент получава един OncoSeek тест за свой роднина като подарък. Научете повече 👇
nmgenomix.com/nm-genomix-%...
MammaPrint + BluePrint genomic profiling predicts anthracycline chemotherapy benefit in HR+HER2- early-stage breast cancer
https://cancerletter.com/clinical-roundup/20260702_7a/
https://cancerletter.com/clinical-roundup/20260702_7a/
MammaPrint + BluePrint genomic profiling predicts anthracycline chemotherapy benefit in HR+HER2- early-stage breast cancer - The Cancer Letter
MammaPrint + BluePrint can help identify a subset of patients with hormone receptor positive, HER2-negative early-stage breast cancer most likely to benefit from anthracycline-based chemotherapy, according to the results of the prospective FLEX Study (NCT03053193). To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login […]
cancerletter.com
July 3, 2026 at 1:00 PM
MammaPrint + BluePrint genomic profiling predicts anthracycline chemotherapy benefit in HR+HER2- early-stage breast cancer
https://cancerletter.com/clinical-roundup/20260702_7a/
https://cancerletter.com/clinical-roundup/20260702_7a/
NCCN updates guidelines recognizing MammaPrint to guide personalized anthracycline use in HR+/HER2- early‑stage breast cancer
https://cancerletter.com/clinical-roundup/20260206_8a/
https://cancerletter.com/clinical-roundup/20260206_8a/
NCCN updates guidelines recognizing MammaPrint to guide personalized anthracycline use in HR+/HER2- early‑stage breast cancer - The Cancer Letter
The NCCN added MammaPrint + BluePrint to the Clinical Practice Guidelines in Oncology for the identification of a subset of hormone receptor positive, HER2-negative early-stage breast cancer patients most likely to benefit from anthracycline-based chemotherapy. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login […]
cancerletter.com
February 9, 2026 at 4:30 PM
NCCN updates guidelines recognizing MammaPrint to guide personalized anthracycline use in HR+/HER2- early‑stage breast cancer
https://cancerletter.com/clinical-roundup/20260206_8a/
https://cancerletter.com/clinical-roundup/20260206_8a/
MammaPrint predicts chemotherapy benefit in HR+HER2 early breast cancer patients, observational FLEX study finds
https://cancerletter.com/clinical-roundup/20250905_12b/
https://cancerletter.com/clinical-roundup/20250905_12b/
MammaPrint predicts chemotherapy benefit in HR+HER2 early breast cancer patients, observational FLEX study finds - The Cancer Letter
The MammaPrint, a gene expression profiling test, predicts the benefit of chemotherapy for patients with hormone receptor-positive, HER2-negative early-stage breast cancer, according to findings published in JNCI Cancer Spectrum. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for a sponsored account.**Not […]
cancerletter.com
September 9, 2025 at 8:00 PM
MammaPrint predicts chemotherapy benefit in HR+HER2 early breast cancer patients, observational FLEX study finds
https://cancerletter.com/clinical-roundup/20250905_12b/
https://cancerletter.com/clinical-roundup/20250905_12b/